NASHVILLE, Tennessee, August 10, 2026
Insight Molecular Diagnostics, Inc. (iMDx) reported second-quarter 2026 results and provided an update on the ongoing U.S. Food and Drug Administration (FDA) review of GraftAssureDx, its investigational kitted donor-derived cell-free DNA (dd-cfDNA) transplant monitoring assay. The company said the FDA completed the current portion of its substantive review in late July and requested additional information as part of the regulatory process. iMDx characterized the company as being in the later stages of the FDA review, with discussions progressing around a defined set of remaining items. GraftAssureDx is designed to enable transplant centers to perform dd-cfDNA testing locally using a digital PCR-based kit, potentially reducing reliance on send-out testing and enabling faster access to results for transplant physicians. The company said its regulatory submission was, to its knowledge, the first kitted dd-cfDNA assay submitted for FDA authorization, following approximately three years of product development.
Medicare Policy Expands GraftAssureDx Market Opportunity
Insight Molecular Diagnostics also highlighted favorable developments in Medicare reimbursement that could expand the potential market for GraftAssureDx if FDA authorization is obtained. A MolDX local coverage decision issued in July 2026 expanded reimbursement for dd-cfDNA surveillance testing, including increased testing frequency during the second and third years following kidney transplantation. The policy allows up to four tests per year during those periods and provides for subsequent testing frequency based on peer-reviewed literature and professional society guidelines. MolDX also confirmed reimbursement coverage for treatment-response monitoring, an application that could allow clinicians to use dd-cfDNA testing to monitor patients receiving anti-rejection therapies. iMDx believes the combination of reimbursement clarity and increasing clinical evidence could encourage major U.S. reference laboratories and transplant centers to consider in-house dd-cfDNA testing. The company is positioning GraftAssureDx as a potential alternative to centralized send-out testing, allowing hospital laboratories to process samples locally and potentially deliver transplant monitoring results more rapidly.
Clinical Data Strengthen GraftAssure Technology
Recent clinical and analytical publications have added support to the potential utility of GraftAssure across transplant monitoring applications. A multicenter study involving eight transplant centers in Germany and Austria evaluated 70 kidney transplant recipients treated with daratumumab for microvascular inflammation and antibody-mediated rejection and used GraftAssure to monitor therapeutic response. iMDx said dd-cfDNA levels declined early during treatment alongside stabilization of kidney function. Data published in the American Journal of Transplantation on the company’s GraftAssure Combination Model Score showed a positive predictive value of 81%, compared with a 54% published benchmark for single-metric dd-cfDNA measurement, while maintaining a 91% negative predictive value. Separately, a Clinical Chemistry publication reported 99.2% agreement between GraftAssure’s digital PCR technology and a leading next-generation sequencing-based competitor assay, while demonstrating higher analytical sensitivity and a lower limit of quantification. The company is also evaluating GraftAssure through its GALACTIC registry and is exploring applications beyond kidney transplantation, including heart transplant monitoring.
iMDx Reports Q2 Revenue and $18.7 Million Cash Balance
iMDx reported approximately $239,000 in revenue for the second quarter of 2026, primarily generated from laboratory services, while research-use-only kit sales contributed approximately $21,000. Gross profit was $157,000, representing a 65.7% gross margin. Operating expenses totaled $11.6 million, including non-cash charges related to contingent consideration, stock-based compensation and depreciation and amortization. Research and development expenses declined 9% sequentially to $4.5 million, reflecting the completion of major FDA submission activities, while sales and marketing expenses decreased sequentially to $1.9 million. The company reported a net loss of $11.3 million, or $0.31 per share, and an adjusted net loss of $8.3 million, or $0.23 per share. Cash, cash equivalents and restricted cash totaled $18.7 million at the end of Q2, while operating cash use was $9.3 million. The ongoing FDA review, expanded Medicare reimbursement framework and growing clinical evidence represent key catalysts for iMDx as it prepares for the potential commercialization of GraftAssureDx and broader adoption of local dd-cfDNA transplant monitoring.
Source:iMDx press release



